Brazil is the biggest country in Latin America in terms of area, population and pharmaceutical market.
Population is approximately 213 million, with a growth rate of 0.7% (2026).
Brasília is the capital, while São Paulo is the most populous city, with approximately 46 million people in its metropolitan region (2026).
The total pharmaceutical market is approximately USD 40 billion.
Driven by an aging population and strong demand for generics, the Brazilian market is projected to grow at a CAGR of 8.77% through 2032, reaching approximately USD 73.79 billion.
Brazil ranks among the world's largest pharmaceutical markets by revenue, according to industry sources including Sinduspharma and Statista.
Accelerated growth is supported by an aging population, with people over 60 expected to represent around 25% of the population by 2034, alongside rising demand for chronic disease treatments.
Retail pharmacies account for approximately 66% of revenue and 89% of units sold, while public procurement through hospitals and clinics represents the remaining 34% of revenue.
Generics and similar drugs account for roughly 70% of total units sold, highlighting strong demand for affordable medicines.
The pharmaceutical sector is heavily regulated, with strict regulations and government-approved pricing for new and existing medicines through CMED.